Trial Profile

Phase IIA Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Familial adenomatous polyposis
Focus Adverse reactions; Therapeutic Use
Sponsors Emtora Biosciences

Most Recent Events

12 May 2025 According to a Biodexa Pharmaceuticals media release, company announced the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis.
09 Jan 2025 Status changed from recruiting to active, no longer recruiting.
17 Jul 2024 Planned End Date changed from 1 Feb 2023 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com